<ul>
	<li>Vascular risks: Stop this tablet if a thrombotic event occurs. Stop this tablet at least 4 weeks before and through 2 weeks after major surgery. Start this tablet no earlier than 4 weeks after delivery, in women who are not breastfeeding.</li>
	<li>Liver disease: Discontinue this tablet if jaundice occurs.</li>
	<li>High blood pressure: Do not prescribe this tablet for women with uncontrolled hypertension or hypertension with vascular disease.</li>
	<li>Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking this tablet. Consider an alternate contraceptive method for women with uncontrolled dyslipidemia.</li>
	<li>Headache: Evaluate significant change in headaches and discontinue this tablet if indicated.</li>
	<li>Uterine bleeding: Evaluate irregular bleeding or amenorrhea.</li>
	<li>CYP3A4 induction: Women taking strong CYP3A4 inducers (for example, carbamazepine, phenytoin, rifampicin, and St. John&rsquo;s wort) should not choose this tablet as their oral contraceptive due to the possibility of decreased contraceptive efficacy.</li>
</ul>